Fractyl Health, Inc. GUTS
- Market cap
- $76.4M
- P/E
- 0.0×
Follow GUTS
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 1.74 | 0.83 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | 14.50 | 3.03 |
High Price
|
|||
| — | — | — | — | — | — | 94 | 102 | 107 | 100 |
Employees
|
|||
| — | — | — | — | — | — | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | 0 | 0 | — |
Revenue
|
|||
| — | — | — | — | — | — | — | 35.83% | 46.24% | — |
Gross Margin
|
|||
| — | — | — | — | — | — | (46) | (77) | (69) | (141) |
EBT
|
|||
| — | — | — | — | — | — | 0.00% | (64,242.50%) | (73,864.52%) | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | (46) | (77) | (69) | (141) |
Net Income
|
|||
| — | — | — | — | — | — | 0 | 0 | 1 | 1 |
Depreciation
|
|||
| — | — | — | — | — | — | 0.00 | 0.06 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | (23.34) | (45.29) | (1.62) | (1.86) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | (23.24) | (20.58) | (1.50) | (1.19) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | (0.03) | (0.17) | (0.04) | (0.01) |
Capex/Sh
|
|||
| — | — | — | — | — | — | (23.27) | (20.75) | (1.55) | (1.20) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | (126.79) | (156.20) | 0.65 | 0.12 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | 2 | 2 | 44 | 76 |
Shares
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | — |
PE Ratio
|
|||
| — | — | — | — | — | — | — | 225.09 | 964.48 | — |
PS Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 3.16 | — |
PB Ratio
|
|||
| — | — | — | — | — | — | — | 405.32 | 563.38 | — |
EV/Sales
|
|||
| — | — | — | — | — | — | — | (1.13) | (0.78) | — |
EV/FCF
|
|||
| — | — | — | — | — | — | (46) | (43) | (66) | (90) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | 0 | 0 | (2) | (1) |
Capex
|
|||
| — | — | — | — | — | — | (46) | (43) | (67) | (91) |
FCF
|
|||
| — | — | — | — | — | — | 44 | 24 | 52 | 69 |
Working Cap'
|
|||
| — | — | — | — | — | — | 18 | 55 | 30 | 31 |
Total Debt
|
|||
| — | — | — | — | — | — | (32) | 22 | (37) | (51) |
Net Debt
|
|||
| — | — | — | — | — | — | (252) | (325) | 28 | 9 |
Sh' Equity
|
|||
| — | — | — | — | — | — | 0.00% | (137.45%) | (74.55%) | (122.85%) |
ROA
|
|||
| — | — | — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | 0.00% | 32.65% | 46.32% | (744.17%) |
ROE
|
|||
Fractyl Health, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| FBIO Fortress Biotech, Inc. | $76.0M | 0.7× | Compare |
| MAIA MAIA Biotechnology, Inc. | $76.0M | 0.0× | Compare |
| RNXT RenovoRx, Inc. | $75.8M | 0.0× | Compare |
| IBIO iBio, Inc. | $77.3M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ACET Adicet Bio, Inc. | $77.4M | 0.0× | Compare |
| OSTX OS Therapies Incorporated | $77.7M | 0.0× | Compare |
| VRCA Verrica Pharmaceuticals Inc. | $74.9M | 0.0× | Compare |
| RNTX Rein Therapeutics Inc. | $73.8M | 0.0× | Compare |
Fractyl Health, Inc. (GUTS) key facts
- Fractyl Health, Inc. (GUTS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Fractyl Health, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $93,000.00, down 22.5% from fiscal 2023.
- As of September 25, 2026, GUTS traded at $0.49, a market capitalization of $76.4 million.
- Return on equity was −744.2% and debt-to-equity -18.29.
Fractyl Health, Inc. (GUTS) Latest News
1 Sep
Fractyl Health targets 2028 launch of Revita for post-GLP-1 weight maintenance. Planned Revita launch marks major strategic move into post-GLP-1 weight maintenance market.
20 Aug
Fractyl Health, Inc. (GUTS) will host a Virtual Commercial Strategy Day on Tuesday, September 1, 2026, to outline the path to commercializing Revita®, a procedural therapy for post-GLP-1 weight maintenance. Upcoming strategy day on Revita commercialization path may moderately influence future market positioning and investor outlook.
14 Aug
Fractyl Health targets Q4 Revita data readout and launches Rejuva gene therapy trial. Q4 Revita data and Rejuva trial launch represent key pipeline milestones with potential to drive substantial valuation changes.
11 Aug
Fractyl Health Inc reported Q2 2026 earnings with pivotal data remaining on track. Pivotal data on track signals major clinical progress with potential to shift company trajectory.
Fractyl Health, Inc. (GUTS) held Q2 2026 earnings call covering financial results, operations, and outlook. Earnings call details provide updates on financial performance that can moderately affect near-term stock movement.
10 Aug
Fractyl Health Q2 earnings call covered financial results, operational progress on Revita and other programs, cash position details, and forward-looking clinical and commercialization plans. Quarterly earnings call supplies performance data and guidance that can shift short-term sentiment without guaranteeing major strategic shifts.
Fractyl Health, Inc. reported second quarter 2026 financial results and business updates. Quarterly financial results and updates offer key data on performance that can shift near-term investor views.
16 Jul
Fractyl Health stock rose after one-year Revita study results showed positive outcomes supporting further development. Positive clinical data directly lifts stock and strengthens long-term product prospects.
15 Jul
Fractyl Health announced Revita helped patients maintain weight loss after stopping GLP-1 medications. Positive Revita data on post-GLP-1 weight maintenance strengthens Fractyl's positioning in metabolic disease treatments.
Fractyl Health reports positive randomized REMAIN-1 midpoint cohort data showing durable weight maintenance one year after GLP-1 discontinuation. Positive randomized data on durable weight maintenance directly validates core therapy and can materially lift company trajectory and investor sentiment.
11 Jun
Fractyl Health Inc (GUTS) received clearance to initiate the RJVA-001 Trial. Funding requirements and sources for the trial are reviewed. Trial clearance enables advancement of RJVA-001 and can materially shift development timeline and investor sentiment.
4 Jun
Fractyl Health reported positive one-year REVEAL-1 open-label results demonstrating sustained weight maintenance after GLP-1 discontinuation following a single Revita procedure. Positive REVEAL-1 data strengthen Revita's positioning in post-GLP-1 weight maintenance and may materially lift company trajectory.
16 May
Fractyl Health shares rose 14% after the company reported a successful first GLP-1 gene therapy trial and a turnaround to profitability. Positive GLP-1 gene therapy trial results plus profit turnaround signal major growth potential in the diabetes and obesity markets.
14 May
Fractyl Health (GUTS) valuation reviewed after FDA approval for new gene therapy trial and first quarter net income report. Gene therapy trial approval and Q1 net income represent major regulatory and financial milestones likely to boost stock performance and investor confidence.
13 May
Fractyl Health, Inc. (GUTS) held its Q1 2026 earnings call covering financial results, operational updates and forward guidance for investors. Q1 2026 earnings call delivers core financial metrics and strategy details that drive stock valuation and investor positioning.
Fractyl Health Inc (GUTS) Q1 2026 earnings call highlighted pivotal trial progress, key operational updates, and strategic advancements. Pivotal trial progress marks a significant milestone toward regulatory approval and commercialization, poised to elevate market performance.
12 May
Fractyl Health released Q1 earnings call highlights covering financial results, pipeline progress, and strategic updates for the obesity treatment company. Q1 earnings highlights disclose financial metrics, clinical advancements, and guidance that could significantly sway investor sentiment and stock trajectory.
Fractyl Health, Inc. (GUTS) reported first quarter 2026 financial results and provided business updates. Quarterly financial results and business updates represent major disclosures that significantly influence investor sentiment and company trajectory.
11 May
Fractyl Health, Inc. (GUTS) authorized to start first-in-human trial of RJVA-001 gene therapy in the Netherlands, the first candidate entering clinical development for Type 2 Diabetes. First-in-human trial authorization for the pioneering gene therapy targeting Type 2 Diabetes fundamentally redefines Fractyl Health's competitive edge and long-term prospects.
25 Mar
Fractyl Health, Inc. (GUTS) Q4 2025 earnings call summary highlights financial results, operational progress, pipeline updates, and forward guidance for the metabolic disease therapy company. Q4 earnings call summaries disclose critical financials, clinical milestones, and strategic outlook that drive significant shifts in valuation and investor confidence.
24 Mar
Fractyl Health, Inc. (GUTS) released highlights from its Q4 earnings call, covering financial results, operational updates, and forward-looking guidance. Q4 earnings call highlights detail financial performance and strategic outlook, poised to significantly influence investor sentiment and stock trajectory.
Fractyl Health, Inc. (GUTS) reported fourth quarter and full year 2025 financial results alongside business updates. Quarterly and annual financial results with business updates directly affect financial performance, investor sentiment, and stock trajectory.
Fractyl Health Inc (GUTS) Q4 2025 earnings call highlights detail efforts to navigate financial challenges. Q4 2025 earnings highlights reveal financial challenges moderately impacting financial performance and market sentiment.
26 Feb
Fractyl Health completed randomization in the REMAIN-1 pivotal cohort for Revita®, a therapy targeting weight maintenance after GLP-1 treatments. Completing randomization in the REMAIN-1 pivotal trial advances Revita® toward potential approval in the high-demand post-GLP-1 weight maintenance market.
23 Feb
Fractyl Health, Inc. (GUTS) stock plunged 77.6% in four weeks due to market pressures, but technical indicators and catalysts signal a potential trend reversal soon. 77.6% stock drop creates volatility, while reversal signals could moderately boost investor sentiment and near-term performance.
30 Jan
Fractyl Health, Inc. (GUTS) is testing its Revita technology to determine if it can improve weight maintenance economics following GLP-1 treatments. The company aims to address the challenges of sustaining weight loss achieved through these medications, potentially redefining the landscape of obesity management. Revita's effectiveness in this context could influence future treatment protocols and market dynamics. Revita's potential to enhance post-GLP-1 weight maintenance could significantly impact Fractyl's market positioning and financial performance.
29 Jan
Fractyl Health, Inc. presented six-month data from its REMAIN-1 study, demonstrating that its Revita treatment effectively mitigates weight regain following GLP-1 therapy. The findings suggest that Revita may offer a significant advantage in managing weight for patients who have undergone GLP-1 treatment, potentially enhancing its market position in obesity management. The data indicates a significant advancement in weight management solutions, which could enhance Fractyl's competitive positioning and market appeal.
Fractyl Health, Inc. (GUTS) announced positive results from its 6-month randomized REMAIN-1 trial, demonstrating that patients maintained weight loss after discontinuing GLP-1 medications when treated with Revita®. The data indicates that Revita® can provide durable weight maintenance, highlighting its potential as a significant therapeutic option for obesity management. The positive trial results for Revita® could significantly enhance Fractyl Health's market position and investor sentiment in the obesity treatment sector.
Fractyl Health, Inc. (GUTS) has been identified as one of the most active stocks in recent trading sessions, indicating heightened investor interest and market activity surrounding the company. This increased activity may reflect broader trends in the healthcare sector or specific developments related to Fractyl's operations and strategic initiatives. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.
6 Jan
Fractyl Health, Inc. has appointed Lara Smith Weber as Chief Financial Officer to enhance its commercial-stage readiness. Weber brings extensive experience in finance and operations, having previously held leadership roles at various healthcare companies. Her appointment is expected to support Fractyl's strategic initiatives as it advances its innovative therapies aimed at treating metabolic diseases. The appointment of a seasoned CFO is a significant strategic move that could enhance Fractyl's operational efficiency and market positioning.